Daily tea intake | Total | No intake | Low intake b | Moderately low intake b | Moderately high intake b | High intake b | P trend c | Per 100 mls |
---|---|---|---|---|---|---|---|---|
Number of participants | 299890 | 99667 | 58966 | 54485 | 52280 | 34492 | ||
Number of breast cancers | 9344 | 3043 | 1704 | 1738 | 1680 | 1179 | ||
Premenopausal breast cancers | ||||||||
Adjusted Hazard Ratio (95% CI)d | 0.90 (0.73-1.12) | 1.00 | 0.98 (0.80-1.21) | 0.97 (0.79-1.20) | 0.98 (0.77-1.26) | 0.624 | 1.00 (0.98-1.03) | |
Postmenopausal cancers | 8407 | 2771 | 1486 | 1566 | 1510 | 1074 | ||
Adjusted Hazard Ratio (95% CI)e | 0.99 (0.92-1.06) | 1.00 | 1.00 (0.93-1.08) | 0.98 (0.91-1.06) | 0.95 (0.88-1.03) | 0.375 | 1.00 (0.99-1.00) | |
ER+ and PR+ subtype | 2817 | 903 | 496 | 477 | 543 | 398 | ||
Adjusted Hazard Ratio (95% CI)f | 1.03 (0.91-1.15) | 1.00 | 0.98 (0.86-1.11) | 1.05 (0.93-1.19) | 1.02 (0.89-1.17) | 0.866 | 1.00 (0.99-1.02) | |
ER- and PR- subtype | 959 | 268 | 177 | 182 | 180 | 152 | ||
Adjusted Hazard Ratio (95% CI)g | 1.12 (0.91-1.38) | 1.00 | 0.99 (0.80-1.22) | 1.03 (0.83-1.27) | 1.12 (0.89-1.42) | 0.941 | 1.00 (0.98-1.02) | |
Analysis by cohort-wide intake | ||||||||
Adjusted Hazard Ratio (95% CI)h | 0.91 (0.74-1.13) | 1.00 | 1.04 (0.85-1.27) | 0.94 (0.75-1.17) | 0.97 (0.75-1.25) | 0.770 | 1.00 (0.98-1.03) | |
Adjusted Hazard Ratio (95% CI)i | 1.01 (0.93-1.09) | 1.00 | 1.01 (0.94-1.10) | 1.01 (0.93-1.10) | 0.99 (0.91-1.08) | 0.998 | 1.00 (0.99-1.00) |